|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1445 New York Avenue, NW, #800 |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1331-12
|
||||||||
|
6. House ID# 303290000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Shawn Friesen |
Date | 4/22/2019 4:50:32 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription.
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting.
Lobby members of Congress regarding issues related to telemedicine.
Advocate for increased transparency regarding drug pricing.
Lobby members of the House to join the Congressional Skin Cancer Caucus.
Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps.
Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks.
Support H.R. 1959, Preserving Patient Access to Compounded Medications Act.
Support reintroduction of Restoring Patients Voice Act.
Support H.R. 1035, Prescription Drug Price Transparency Act.
Support H.R. 985, Fair Access for Safe and Timely Generics Act.
Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act.
Support reintroduction of Patients Access to Treatments Act.
Support S. 476, C-THRU Act.
Support S. 989, Ensuring Childrens Access to Specialty Care Act.
Support H.R. 1034/S. 640, Phair Pricing Act.
Support S. 657, Drug Price Transparency Act
Support H.R. 938, BLOCKING Act
Support S. 64, Preserve Access to Affordable Generics & Biosimilars Act
Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act.
Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans.
Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act.
Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs.
Advocate for access to dermatological procedures for veterans through the VA MISSION Act (P.L. 115-182).
Advocate for the continued funding of Community Health Centers.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill.
Advocate for the study of indoor tanning in qualified physical fitness centers.
Advocate for funding for tele-dermatology devices at Indian Health Services Health Centers.
Advocate for the Health Resources and Services Administration to study specialty physician shortages.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage.
Advocate for increased funding and reforms to Graduate Medical Education.
Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration.
Lobby members of Congress regarding improvements to Health Information Technology implementation.
Advocate for improving disease management and care coordination for patients with chronic diseases.
Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception.
Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110)
Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019
Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS).
Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans.
Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs).
Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs.
Advocate in support of nomination of Michael Bigby, MD, to serve as Commissioner on the Medicare Payment Advisory Commission.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Government Accountability Office (GAO), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.1085/H.R.1922, Restoring Access to Medication Act and H.R. 6199, the Restoring Access to Medication and Modernizing Health Savings Accounts Act of 2018.)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription.
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting.
Support H.R. 1959, Preserving Patient Access to Compounded Medications Act.
Support H.R. 1035, Prescription Drug Price Transparency Act
Support S. 476, C-THRU Act.
Support H.R. 1034/S. 640, Phair Pricing Act
Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act
Support S. 657 Drug Price Transparency Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Michelle |
Mathy |
|
|
|
Blake |
McDonald |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program, included in the VA MISSION Act (Public Law No: 115-182).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Michelle |
Mathy |
|
|
|
Blake |
McDonald |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill.
Advocate for the study of indoor tanning in qualified physical fitness centers.
Advocate for funding for tele-dermatology devices at Indian Health Services Health Centers.
Advocate for the Health Resources and Services Administration to study specialty physician shortages.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |